NCT05476029

Changes of Exosomes and Biomarkers in Plasma and Alveolar Lavage Fluid of Patients With Sepsis Complicated With ARDS

Status unknown Last updated 27 July 2022

What this trial tests

trial testing Blood samples and alveolar lavage fluid were collected in Sepsis Complicated With ARDS in 20 participants. Status unknown.

Timeline

25 July 2022

Primary endpoint
30 May 2023

30 December 2023

Quick facts

Lead sponsor	Tianjin Nankai Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	20
Start date	25 July 2022
Primary completion	30 May 2023
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

• Blood samples and alveolar lavage fluid were collected

Conditions studied

• Sepsis Complicated With ARDS — all drugs for Sepsis Complicated With ARDS →

Sponsor

Tianjin Nankai Hospital

Who can join

18 and older, any sex, with Sepsis Complicated With ARDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, serum samples and alveolar lavage fluid from patients with sepsis complicated with ARDS were studied. The differential miRNAs of inflammatory exosomes in patients with sepsis lung injury were screened, and Sestrin2, HO-1 and PPARγ proteins, oxidative stress and inflammatory indexes in serum and alveolar lavage fluid were measured simultaneously, to explore the relationship between HO-1, oxidative inflammatory indexes and metabolic indexes. These results provide an important reference for assisting the management of ARDS disease and predicting the adverse outcomes of sepsis patients with ARDS.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.
   Huang Y, Guo X, Wu Y, Chen X, et al · · 2024 · cited 188× · PMID 38378653 · DOI 10.1038/s41392-024-01745-z
2. Engineered and Mimicked Extracellular Nanovesicles for Therapeutic Delivery.
   Poinsot V, Pizzinat N, Ong-Meang V. · · 2024 · cited 16× · PMID 38607173 · DOI 10.3390/nano14070639
3. Advancements in extracellular vesicles biomanufacturing: a comprehensive overview of large-scale production and clinical research.
   Li Z, Yan J, Li X, Chen H, et al · · 2025 · cited 7× · PMID 40046812 · DOI 10.3389/fbioe.2025.1487627
4. Bio fluid exosomes: promises, challenges, and future directions in translational medicine.
   Soltanmohammadi F, Maghsoodi M, Alizadeh E, Adibkia K, et al · · 2025 · cited 6× · PMID 40988065 · DOI 10.1186/s12967-025-06886-5
5. Harnessing Extracellular microRNAs for Diagnostics and Therapeutics in Acute Systemic Inflammation.
   Hollis R, Aziz M, Jacob A, Wang P. · · 2024 · cited 5× · PMID 38534389 · DOI 10.3390/cells13060545
6. Effect Analysis of Extracellular Vesicles in the Treatment of Bronchopulmonary Dysplasia via Different Drug Delivery and Administration Routes.
   Xu W, Chen S, Liang T, Kang L, et al · · 2025 · PMID 41019235 · DOI 10.2147/ijn.s530819